{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"37.4","upperLimit":"59.2","value":"48.3"},{"groupId":"OG001","lowerLimit":"1.2","upperLimit":"30.4","value":"9.5"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"33.6","value":"0.0"},{"groupId":"OG003","lowerLimit":"0.6","upperLimit":"80.6","value":"25.0"},{"groupId":"OG004","lowerLimit":"18.4","upperLimit":"67.1","value":"41.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"17"}],"units":"Participants"}],"description":"A supportive efficacy endpoint is confirmed radiographic ORR by INV. ORR is defined as the percentage of patients with a confirmed CR (complete response) or PR (partial response) by mRECIST (modified Response Evaluation Criteria in Solid Tumors) v1.1/PCWG3 (Prostate Cancer Working Group 3) criteria. The confirmed response is defined as a CR or PR on subsequent tumor assessment at least 28 days after first response documentation in the absence of confirmed progression in bone. CR is disappearance of all target and non-target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm. PR is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with a deleterious BRCA (breast cancer susceptibility gene) mutation detected in their tumor.","id":"OG000","title":"BRCA Mutation"},{"description":"Patients with a deleterious ATM (ataxia telangiectasia mutated serine/threonine kinase) mutation detected in their tumor.","id":"OG001","title":"ATM Mutation"},{"description":"Patients with a deleterious CDK12 (Cyclin-dependent kinase 12) mutation detected in their tumor.","id":"OG002","title":"CDK12 Mutation"},{"description":"Patients with a deleterious CHEK2 (Checkpoint Kinase 2) mutation detected in their tumor.","id":"OG003","title":"CHEK2 Mutation"},{"description":"Patients with other deleterious HRR (homologous recombination repair) gene mutation detected in their tumor.","id":"OG004","title":"Other Gene Mutation"}],"paramType":"NUMBER","populationDescription":"Investigator Efficacy Population - The Investigator efficacy population is defined by measurable disease status at baseline using modified RECIST Version 1.1 criteria per the investigator (INV).","reportingStatus":"POSTED","timeFrame":"Assessments every 8 weeks from study day 1 for the first 24 weeks, and then every 12 weeks until disease progression, death, or initiation of subsequent treatment. Total follow-up was up to approximately 3 years.","title":"Confirmed Objective Response Rate (ORR) by Gene in Patients With Measurable Disease at Baseline Per Investigator (INV)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}